NCT05891795View on ClinicalTrials.gov

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acne Vulgaris
Interventions
DRUG

Clascoterone 1% Top Cream

Apply a thin layer to the affected area twice daily.

DRUG

Vehicle

Apply a thin layer to the affected area twice daily.

Trial Locations (1)

94305

RECRUITING

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER